LifeSci Capital Keeps Their Buy Rating on Rocket Pharmaceuticals (RCKT)
Confident Investing Starts Here:
Jubinville, PhD covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Rocket Pharmaceuticals, and Mereo Biopharma Group Plc. According to TipRanks, Jubinville, PhD has an average return of -13.5% and a 29.41% success rate on recommended stocks.
In addition to LifeSci Capital, Rocket Pharmaceuticals also received a Buy from Bank of America Securities's Jason Zemansky in a report issued on May 28. However, yesterday, Evercore ISI downgraded Rocket Pharmaceuticals (NASDAQ: RCKT) to a Hold.
Based on Rocket Pharmaceuticals' latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $61.33 million. In comparison, last year the company had a GAAP net loss of $62.05 million
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RCKT in relation to earlier this year. Earlier this month, John Militello, the VP of Finance, Treasurer, Principal Accounting Officer of RCKT sold 357.00 shares for a total of $2,299.08.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Rocket Pharmaceuticals Reorganizes, Cuts Workforce by 30% to Focus on AAV Cardiovascular Platform
Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the most promising penny stocks under $5. On July 24, Rocket Pharmaceuticals announced a strategic corporate reorganization and pipeline prioritization to focus its resources on its adeno-associated virus/AAV cardiovascular platform and the regulatory submission for KRESLADI (formerly RP-L201) for severe leukocyte adhesion deficiency-I/LAD-I. The company is implementing a workforce reduction of ~30%. This, along with other cost-saving measures, is expected to decrease Rocket's 12-month operating expenses by ~25%. As a result, the company anticipates that its current cash resources will fund operations into Q2 2027. Scientific equipment in a lab setting, revealing the cutting edge of biotechnology research. This estimate does not account for any potential proceeds from a Priority Review Voucher, which may be granted upon the FDA approval of KRESLADI. As part of this realignment, the company anticipates delays in the Fanconi Anemia (FA; RP-L102) and Pyruvate Kinase Deficiency (PKD; RP-L301) programs, with FDA approval for RP-L102 no longer expected in 2026. Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the US. While we acknowledge the potential of RCKT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Entrepreneur
2 days ago
- Entrepreneur
Google AI Pioneer Employee Says to Stay Away From AI PhDs
Jad Tarifi, who founded Google's first generative AI team and has a Ph.D. from the University of Florida, wouldn't recommend starting a program now. AI researchers are in high demand, with some offered billion-dollar compensation packages from Meta amid the ongoing AI talent wars. However, one AI pioneer, Jad Tarifi, who founded Google's first generative AI team after obtaining a Ph.D. in AI, would not recommend higher study to break into the field. In a new interview with Business Insider, Tarifi, 42, predicted that within the five to seven years it takes to obtain a Ph.D., most of AI's problems will be solved. "Even things like applying AI to robotics will be solved by then," Tarifi told BI. Related: AI Is Going to 'Replace Everybody' in Several Fields, According to the 'Godfather of AI.' Here's Who He Says Should Be 'Terrified.' Tarifi explained that obtaining a Ph.D. was only for "weird people" who were "obsessed" with a certain field because higher education required "a lot of pain" and at least five years of their lives. He recommended staying away from the Ph.D. route altogether or choosing to specialize in a subfield of AI that is still in its early stages, like AI for biology. Tarifi received a Ph.D. in 2012 from the University of Florida, where he worked on an AI theory that combined principles from neuroscience, geometry, and machine learning, according to his LinkedIn. He then joined Google, where he became a tech lead and manager for nearly a decade, working on models for Google's generative AI projects. Tarifi is now the founder and CEO of Integral AI, a startup that focuses on creating AI agents to act autonomously on behalf of users. Related: These 3 Professions Are Most Likely to Vanish in the Next 20 Years Due to AI, According to a New Report In the BI interview, Tarifi also warned prospective students from completing degrees in law and medicine, arguing that the information in these programs was "outdated" and memorization-based. Tarifi isn't the first person to warn students away from higher degrees. Venture capitalist Victor Lazarte said earlier this year that AI is "fully replacing people" in the legal profession. He predicted that AI would take over entry-level legal positions usually filled by recent law school graduates within the next three years. Join top CEOs, founders and operators at the Level Up conference to unlock strategies for scaling your business, boosting revenue and building sustainable success.
Yahoo
5 days ago
- Yahoo
Rivian's CEO explains why he got a Ph.D. — and why he chose MIT over Stanford
Rivian CEO RJ Scaringe said that his Ph.D. from MIT gave him "credibility" when approaching investors. Scaringe told the "Tosh Show" that he went to Stanford for a day before switching over to MIT for their automotive program. "It was like being recruited for a nerd sports team," Scaringe said of choosing between MIT and Stanford. Some people pursue Ph.D.s to work in academia or to attain lofty research positions. The CEO of Rivian got his so people would take him seriously. RJ Scaringe founded Mainstream Motors — later renamed Rivian — in 2009. It took over a decade to collect capital, build manufacturing capabilities, and eventually distribute the company's first consumer electric vehicle, the R1T. When pitching his EV company to investors, Scaringe had a résumé perk: his Ph.D. from Massachusetts Institute of Technology. On the "Tosh Show," Scaringe said that he figured the degree would put him in good standing in investor rooms. "I thought, 'I'll need a lot of money. I don't have any money, and if I'm going to get other people to invest money into this thing that I want to build, me having a Ph.D. from MIT or equivalent makes that more likely,'" Scaringe said. Pitching a vehicle company is difficult, as Scaringe described on the podcast. Given the upfront capital costs to make a basic prototype, EV entrepreneurs like Scaringe are often pitching an idea more than a discreet product. Thus, EV founders need credibility — and Scaringe didn't want to wait decades. "I didn't want to go work at a car company for 20 years and earn credibility," he said. "So I wanted to get like credibility as quickly as I could." For Scaringe, that came in the form of a Ph.D. in automotive mechanical engineering. MIT is a hotbed for entrepreneurs. Notable Ph.D. alums include Intel cofounder Robert Noyce and Boston Dynamics founder Marc Raibert. Amar Bose of Bose Corporation got his Sc.D. from the institution. When picking his graduate institution, Scaringe had two options: MIT or Stanford University. Having graduated first in his class at Rensselaer Polytechnic Institute, Scaringe said he had plenty of options and was being courted by various programs. "It was like being recruited for a nerd sports team because MIT offered me this amazing role, Stanford offered me this amazing role," he said. Scaringe accepted his offer from Stanford and enrolled for a day before switching over to MIT. "I actually preferred the program at MIT," Scaringe said. "The reason I really liked what MIT had is that they had an automotive-specific program and a lab built around automotive, and I knew I wanted to start what eventually became Rivian." Scaringe called his reasoning for getting a Ph.D. "wonderfully naive" — but "it worked." Read the original article on Business Insider Sign in to access your portfolio
